AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12399222 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (n=6)
Number of subjects: 15
Study 9657461 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% MCT/LCT fat emulsion
Number of subjects: 25
Study 9657461 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% MCT/LCT fat emulsion
Number of subjects: 25
Study 9657461 — intervention group
Group type: EXPERIMENTAL
Intervention: LCT fat emulsion
Number of subjects: 25
Study 9657461 — intervention group
Group type: COMPARATOR
Intervention: Glucose alone (Control)
Number of subjects: 25
Study 9657461 — intervention group
Group type: EXPERIMENTAL
Intervention: All fat emulsions
Number of subjects: 25
Study 7624387 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine combined with zotepine or haloperidol
Number of subjects: 14
Study 2697729 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral calcium supplementation
Number of subjects: 400
Study 2697729 — intervention group
Group type: COMPARATOR
Intervention: Low-calcium diet
Number of subjects: 400
Study 127542 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA‐S
Number of subjects: 15
Study 127542 — intervention group
Group type: COMPARATOR
Intervention: NaCl (Control)
Number of subjects: 15
Study 31170361 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Intensive Insulin Therapy (IIT)
Number of subjects: 24
Study 31170361 — intervention group
Group type: COMPARATOR
Intervention: Metformin (Control)
Number of subjects: 24
Study 28616851 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic interval training for 8 weeks
Number of subjects: 40
Study 28616851 — intervention group
Group type: COMPARATOR
Intervention: Non-exercising control
Number of subjects: 40
Study 26116037 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemetric monitoring
Number of subjects: 40
Study 26116037 — intervention group
Group type: COMPARATOR
Intervention: Traditional medical consultation
Number of subjects: 40
Study 23631965 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid maxillary expansion (2 turns of activation (0.4 mm) per day)
Number of subjects: 33
Study 23631965 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow maxillary expansion (2 turns of activation (0.4 mm) per week until 8 mm of expansion)
Number of subjects: 33
Study 21596190 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketamine S(+) 0.050 mg/kg
Number of subjects: 30
Study 21596190 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketamine S(+) 0.125 mg/kg
Number of subjects: 30
Study 21596190 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketamine S(+) 0.250 mg/kg
Number of subjects: 30
Study 19389820 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 50
Study 19389820 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily injections (MDI) with insulin glargine and lispro
Number of subjects: 50
Study 19389820 — intervention group
Group type: EXPERIMENTAL
Intervention: CSII
Number of subjects: 50
Study 19389820 — intervention group
Group type: COMPARATOR
Intervention: MDI
Number of subjects: 50
Study 17321667 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 77
Study 17321667 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate-specific antigen (PSA)
Number of subjects: 77
Study 15098043 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based medicine (EBM)
Number of subjects: 0
Study 15098043 — intervention group
Group type: EXPERIMENTAL
Intervention: EBM principles and application
Number of subjects: 0
Study 11255387 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibutilide (0.003 mg/kg), infused intravenously for 10 minutes.
Number of subjects: 58
Study 9572724 — intervention group
Group type: EXPERIMENTAL
Intervention: audio computer‐assisted self‐interviewing (audio‐CASI)
Number of subjects: 1690
Study 9572724 — intervention group
Group type: COMPARATOR
Intervention: traditional self‐administered questionnaire
Number of subjects: 1690
Study 8186337 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (30 mg each morning, placebo at bedtime)
Number of subjects: 158
Study 8186337 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (150 mg each morning and at bedtime)
Number of subjects: 158
Study 2896139 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed-release mesalazine
Number of subjects: 100
Study 2896139 — intervention group
Group type: COMPARATOR
Intervention: Enteric-coated sulfasalazine
Number of subjects: 100
Study 31560780 — intervention group
Group type: COMPARATOR
Intervention: MBCT
Number of subjects: 245
Study 31560780 — intervention group
Group type: COMPARATOR
Intervention: eMBCT
Number of subjects: 245
Study 28985228 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle coaching plus care coordination (N = 138)
Number of subjects: 428
Study 28985228 — intervention group
Group type: COMPARATOR
Intervention: Care coordination alone (N = 142)
Number of subjects: 428
Study 28985228 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (N = 148)
Number of subjects: 428
Study 25752936 — intervention group
Group type: EXPERIMENTAL
Intervention: BOLD hypercapnic/hyperoxic responses
Number of subjects: 8
Study 25752936 — intervention group
Group type: EXPERIMENTAL
Intervention: CBF hypercapnic response
Number of subjects: 8
Study 25752936 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting CBF
Number of subjects: 8
Study 23427212 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop anaesthesia system
Number of subjects: 186
Study 23427212 — intervention group
Group type: COMPARATOR
Intervention: Control group (manual administration)
Number of subjects: 186
Study 22352122 — intervention group
Group type: EXPERIMENTAL
Intervention: Early titration (E) with irbesartan/hydrochlorothiazide 150/12.5 mg for 2 weeks, then up-titrated to 300/25 mg at weeks 2 and 6
Number of subjects: 795
Study 22352122 — intervention group
Group type: COMPARATOR
Intervention: Late titration (L) with irbesartan/hydrochlorothiazide 150/12.5 mg for 6 weeks, then up-titrated to 300/25 mg at week 6
Number of subjects: 795
Study 19153936 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cholesterol (TC)
Number of subjects: 2299
Study 19153936 — intervention group
Group type: EXPERIMENTAL
Intervention: Triglycerides (TG)
Number of subjects: 2299
Study 19153936 — intervention group
Group type: EXPERIMENTAL
Intervention: High density lipoprotein cholesterol (HDL-c)
Number of subjects: 2299
Study 19153936 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure
Number of subjects: 2299
Study 19153936 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeostasis model assessment score (HOMA)
Number of subjects: 2299
Study 19153936 — intervention group
Group type: EXPERIMENTAL
Intervention: Clustering of CVD risk factors
Number of subjects: 2299
Study 16679897 — intervention group
Group type: EXPERIMENTAL
Intervention: AQUACEL Ag Hydrofiber dressing with silver
Number of subjects: 84
Study 16679897 — intervention group
Group type: COMPARATOR
Intervention: Silver sulfadiazine
Number of subjects: 84
Study 14765987 — intervention group
Group type: EXPERIMENTAL
Intervention: l-thyroxine treatment regimen
Number of subjects: 11
Study 11083889 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (800‐1200 mg/day)
Number of subjects: 149
Study 11083889 — intervention group
Group type: COMPARATOR
Intervention: Imipenem (2‐4 g/day)
Number of subjects: 149
Study 9068468 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin (250 mg b.i.d.)
Number of subjects: 70
Study 9068468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 9068468 — intervention group
Group type: COMPARATOR
Intervention: Oral ciprofloxacin and Placebo
Number of subjects: 70
Study 9068468 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin treatment
Number of subjects: 70
Study 8251019 — intervention group
Group type: EXPERIMENTAL
Intervention: Prewarmed group (warming blanket for > or = 90 min)
Number of subjects: 16
Study 8251019 — intervention group
Group type: COMPARATOR
Intervention: Unwarmed group (not covered)
Number of subjects: 16
Study 2947734 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiethylperazine (6.5 mg p.o. every 8 h for 5 days)
Number of subjects: 26
Study 2947734 — intervention group
Group type: COMPARATOR
Intervention: Thiethylperazine (6.5 mg p.o. every 8 h for 5 days) plus amitriptyline (25 mg p.o. every 8 h for 5 days)
Number of subjects: 26
Study 31671189 — intervention group
Group type: EXPERIMENTAL
Intervention: Perspective-taking group (observers instructed to take the perspective of the pain participant)
Number of subjects: 122
Study 31671189 — intervention group
Group type: COMPARATOR
Intervention: Control group (no perspective-taking instruction)
Number of subjects: 122
Study 31671189 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (perspective-taking and control)
Number of subjects: 122
Study 29705442 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry capsule
Number of subjects: 60
Study 29705442 — intervention group
Group type: EXPERIMENTAL
Intervention: Training about UTIs
Number of subjects: 60
Study 29705442 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 26777765 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidirectional power toothbrush (PT)
Number of subjects: 107
Study 26777765 — intervention group
Group type: COMPARATOR
Intervention: American Dental Association reference manual toothbrush (MT)
Number of subjects: 107
Study 24509962 — intervention group
Group type: EXPERIMENTAL
Intervention: Sample group (received a demonstration on how to apply the medication using a product sample)
Number of subjects: 17
Study 24509962 — intervention group
Group type: COMPARATOR
Intervention: No sample group (no demonstration)
Number of subjects: 17
Study 24509962 — intervention group
Group type: EXPERIMENTAL
Intervention: Sample group
Number of subjects: 17
Study 24509962 — intervention group
Group type: COMPARATOR
Intervention: No sample group
Number of subjects: 17
Study 22910161 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured training on box trainers
Number of subjects: 40
Study 22910161 — intervention group
Group type: COMPARATOR
Intervention: Traditional training
Number of subjects: 40
Study 21211344 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler-guided hemorrhoidal artery ligation
Number of subjects: 92
Study 21211344 — intervention group
Group type: COMPARATOR
Intervention: Operative procedures for prolapse and hemorrhoids
Number of subjects: 92
Study 18677882 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored feedback letters
Number of subjects: 2827
Study 18677882 — intervention group
Group type: COMPARATOR
Intervention: Generic feedback letters
Number of subjects: 2827
Study 18677882 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored information with action-planning feedback
Number of subjects: 2827
Study 15963129 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlormadinone acetate (CMA+)
Number of subjects: 71
Study 15963129 — intervention group
Group type: COMPARATOR
Intervention: Control (CMA-)
Number of subjects: 71
Study 12575974 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg verapamil
Number of subjects: 30
Study 12575974 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 30
Study 11909562 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold-coated stents (group B, n = 103)
Number of subjects: 204
Study 11909562 — intervention group
Group type: COMPARATOR
Intervention: Uncoated stents (group A, n = 101)
Number of subjects: 204
Study 9819291 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (BUD) at high dose (800 micrograms twice daily)
Number of subjects: 12
Study 9819291 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (TAA) at high dose (800 micrograms twice daily)
Number of subjects: 12
Study 9819291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7641720 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthesia with propofol (Group II)
Number of subjects: 60
Study 7641720 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous propofol supplemented with nitrous oxide (Group III)
Number of subjects: 60
Study 7641720 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone induction, isoflurane and nitrous oxide (Group I)
Number of subjects: 60
Study 2475699 — intervention group
Group type: EXPERIMENTAL
Intervention: Falipamil 100 mg
Number of subjects: 12
Study 2475699 — intervention group
Group type: EXPERIMENTAL
Intervention: Falipamil 200 mg
Number of subjects: 12
Study 2475699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2475699 — intervention group
Group type: EXPERIMENTAL
Intervention: Falipamil
Number of subjects: 12
Study 1093666 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin
Number of subjects: 9
Study 1093666 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil and cyclophosphamide
Number of subjects: 9
Study 1093666 — intervention group
Group type: COMPARATOR
Intervention: Crossover treatment (Adriamycin to 5-fluorouracil and cyclophosphamide)
Number of subjects: 9
Study 31174929 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful Awareness in Body‐oriented Therapy (MABT)
Number of subjects: 10
Study 31174929 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 10
Study 31174929 — intervention group
Group type: EXPERIMENTAL
Intervention: MABT
Number of subjects: 10
Study 31556659 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART (smartphone application)
Number of subjects: 276
Study 31556659 — intervention group
Group type: EXPERIMENTAL
Intervention: GROUP (group-based BWL condition)
Number of subjects: 276
Study 31556659 — intervention group
Group type: COMPARATOR
Intervention: CONTROL (control condition)
Number of subjects: 276
Study 28102014 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (banded two‐arm Hyrax)
Number of subjects: 35
Study 28102014 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (banded four‐arm Hyrax)
Number of subjects: 35
Study 28102014 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (RME)
Number of subjects: 35
Study 26579797 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sodium wheat bread rich in potassium, GABA, and ACEI peptides (LSB+G)
Number of subjects: 30
Study 26579797 — intervention group
Group type: COMPARATOR
Intervention: Conventional wheat bread (CB)
Number of subjects: 30
Study 26579797 — intervention group
Group type: COMPARATOR
Intervention: Low-sodium wheat bread enriched in potassium (LSB)
Number of subjects: 30
Study 24280478 — intervention group
Group type: EXPERIMENTAL
Intervention: Group music therapy (60-min sessions, twice a week for a total of ten sessions)
Number of subjects: 80
Study 24280478 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no music therapy)
Number of subjects: 80
Study 21787474 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuebijing treatment group (n=39, received bundle treatment + Xuebijing treatment)
Number of subjects: 64
Study 21787474 — intervention group
Group type: COMPARATOR
Intervention: Routine group (n=25, received routine bundle treatment)
Number of subjects: 64
Study 19420392 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based intervention promoting physical activity and healthy eating; details on dosage and duration not specified
Number of subjects: 2155
Study 19420392 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 2155
Study 17014519 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold levels recommended by NKF for calcium-phosphate product
Number of subjects: 197
Study 17014519 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold levels recommended by NKF for glycosylated hemoglobin
Number of subjects: 197
Study 17014519 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold levels recommended by NKF for blood pressure
Number of subjects: 197
Study 17014519 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold levels recommended by NKF for hemoglobin
Number of subjects: 197
Study 17014519 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold levels recommended by NKF for parathyroid hormone
Number of subjects: 197
Study 17014519 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold levels recommended by NKF for low-density lipoprotein
Number of subjects: 197
Study 15308996 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 500
Study 15308996 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 500
Study 10694140 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Volume Taper (LVT)
Number of subjects: 8
Study 10694140 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate Volume Taper (MVT)
Number of subjects: 8
Study 10694140 — intervention group
Group type: EXPERIMENTAL
Intervention: Taper LICT
Number of subjects: 8
Study 10694140 — intervention group
Group type: EXPERIMENTAL
Intervention: Taper HIIT
Number of subjects: 8
Study 10694140 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall group
Number of subjects: 8
Study 9463178 — intervention group
Group type: EXPERIMENTAL
Intervention: Guilmen‐Pontonnier suture (Group A)
Number of subjects: 202
Study 9463178 — intervention group
Group type: COMPARATOR
Intervention: Blair‐Donatti suture (Group B)
Number of subjects: 202
Study 8167624 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with DISH
Number of subjects: 25
Study 8167624 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 25
Study 29083139 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D-HyFoSy
Number of subjects: 50
Study 29083139 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-HyFoSy
Number of subjects: 50
Study 26451734 — intervention group
Group type: EXPERIMENTAL
Intervention: Umeclidinium (UMEC; 62.5 g and 125 g) added to Fluticasone Propionate/Salmeterol (FP/SAL; 250/50 g)
Number of subjects: 0
Study 26451734 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO) added to Fluticasone Propionate/Salmeterol (FP/SAL; 250/50 g)
Number of subjects: 0
Study 24378514 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted lopinavir (LPV/r) monotherapy
Number of subjects: 60
Study 24378514 — intervention group
Group type: COMPARATOR
Intervention: LPV/r with optimized background regimens (OBRs)
Number of subjects: 60
Study 24378514 — intervention group
Group type: EXPERIMENTAL
Intervention: History of viral blip during virologic suppression with second-line PI-based regimen
Number of subjects: 60
Study 22042589 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic plication
Number of subjects: 60
Study 22042589 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic fundoplication
Number of subjects: 60
Study 20438516 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional, lactate-buffered, acidic solution (solution D)
Number of subjects: 26
Study 20438516 — intervention group
Group type: COMPARATOR
Intervention: Novel, bicarbonate/lactate-buffered neutral solution (solution P)
Number of subjects: 26
Study 18320351 — intervention group
Group type: EXPERIMENTAL
Intervention: BFR + EXS
Number of subjects: 100
Study 18320351 — intervention group
Group type: EXPERIMENTAL
Intervention: BFR + EXS (female)
Number of subjects: 100
Study 18320351 — intervention group
Group type: COMPARATOR
Intervention: BFR + noEXS
Number of subjects: 100
Study 15661548 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative lymphoscintigraphy
Number of subjects: 823
Study 15661548 — intervention group
Group type: COMPARATOR
Intervention: No preoperative lymphoscintigraphy
Number of subjects: 823
Study 15661548 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative gamma probe
Number of subjects: 823
Study 12356379 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/day
Number of subjects: 103
Study 12356379 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/day
Number of subjects: 103
Study 12356379 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 103
Study 12356379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 10575158 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene cream and gel
Number of subjects: 30
Study 10575158 — intervention group
Group type: EXPERIMENTAL
Intervention: Tretinoin creams and gels
Number of subjects: 30
Study 10575158 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium lauryl sulfate (SLS) 0.1% w/v
Number of subjects: 30
Study 10575158 — intervention group
Group type: COMPARATOR
Intervention: Adapalene
Number of subjects: 30
Study 10575158 — intervention group
Group type: COMPARATOR
Intervention: Petrolatum
Number of subjects: 30
Study 8951962 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray (1.5 micrograms/kg per spray)
Number of subjects: 37
Study 8951962 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine cigarette puffs
Number of subjects: 37
Study 1655156 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyglycolic acid ligatures and muscle and skin closure
Number of subjects: 650
Study 1655156 — intervention group
Group type: COMPARATOR
Intervention: Chromic catgut ligatures and muscle closure, nylon skin closure
Number of subjects: 650
Study 6310983 — intervention group
Group type: EXPERIMENTAL
Intervention: Central parenteral nutrition (CPN)
Number of subjects: 19
Study 6310983 — intervention group
Group type: COMPARATOR
Intervention: Peripheral parenteral nutrition (PPN) plus enteral nutrition
Number of subjects: 19
Study 30212395 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot Medroxyprogesterone Acetate (DMPA)
Number of subjects: 74
Study 30212395 — intervention group
Group type: COMPARATOR
Intervention: Oral Contraceptive Pills (OCP)
Number of subjects: 74
Study 30212395 — intervention group
Group type: COMPARATOR
Intervention: Follicular Phase
Number of subjects: 74
Study 30212395 — intervention group
Group type: COMPARATOR
Intervention: Luteal Phase
Number of subjects: 74
Study 27005937 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS stimulation
Number of subjects: 25
Study 27005937 — intervention group
Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 25
Study 24559194 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate (PP), mean dose/month 70.3 mg eq. (109.6 mg), median duration of exposure 204 days.
Number of subjects: 644
Study 24559194 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate (PP)
Number of subjects: 644
Study 23255849 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent
Number of subjects: 788